Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL
19 Agosto 2024 - 3:55PM
Business Wire
Newman Ferrara LLP announced today that the firm is conducting
an investigation on behalf of shareholders of Zentalis
Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ:ZNTL)
into potential breaches of fiduciary duty by the Company’s Board of
Directors (the “Board”).
Zentalis, headquartered in San Diego, CA, is a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers. Newman Ferrara’s investigation focuses on
decisions made by the Board, without shareholder approval, the
result of which significantly diminish shareholder value and do not
benefit the Company. Considering the Company’s lackluster
performance since 2020, it is clear that the Board lacks the
ability to fairly assess and oversee the Company’s direction and
leadership.
Current Zentalis stockholders seeking more information on this
matter are invited to contact Newman Ferrara attorneys Jeffrey
Norton (jnorton@nfllp.com) or Benjamin Baker (bbaker@nfllp.com) to
discuss this investigation and their rights.
Newman Ferrara maintains a multifaceted practice based in New
York City with attorneys specializing in complex commercial and
multi-party litigation, securities fraud and shareholder
litigation, consumer protection, civil rights, and real estate. For
more information, please visit the firm website at
www.nfllp.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240819223001/en/
Newman Ferrara LLP Benjamin Baker bbaker@nfllp.com 1250
Broadway, 27th Fl. New York, NY 10001 (212) 619-5400
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024